| 
|
With this financing round it is possible to develop the PERKAT™ products further to the first-in-man (FIM) trials. The PERKAT RV device can be implanted to increase cardiac output (CO) of patients, who suffer from acute heart failure due to pulmonary embolism or myocardial infarction. Currently, these patients have an extremely high mortality rate. The MCS improves CO if drug treatment fails to stabilize the hemodynamic condition in such cases. The PERKAT MCS from NovaPump employs a unique self-expanding mechanism of the pump chamber. PERKAT is completely catheter-based, ECG controlled, and combines physiologic pulsatile mechanism and an automated pump mode.
Prof Markus Ferrari (MD), co-founder and inventor of PERKAT explained: “Our heart pumps can be implanted under X Ray control within a few minutes. They work in a pulsatile manner using ECG or pressure trigger to physiologically support the failing human heart. Post CE approval, our devices will be a meaningful application for current IABP (Intra Aortic Balloon Counterpulsation) technology, which is available for treatment in most heart centres worldwide today. The PERKAT heart pumps can further increase our therapeutic options with MCS in cardiogenic shock patients.”
Ronald Reich, founder and CEO added: “We are very pleased about the trust placed in us from our new investors (a global med-tech company) and our seed investors HTGF and bm t. We will use these A round funds to further progress on our next milestones, including the planned clinical trial for our right heart pump and to advance our research collaborations with our R&D partners in the field of short-term mechanical circulation support.”
Dr Martin Pfister, senior investment manager from HTGF commented: “With this investment round NovaPump has attained the necessary budget to develop the PERKAT heart pumps further to the first in man trial. We are pleased to be investing as part of a strong consortium with a global med-tech partner who extends the capabilities of NovaPump with deep industry expertise in this field.”
In Germany alone there are about 250.000 cases of myocardial infarction annually. Over the last two decades, since having modern percutaneous MCS available, the mortality rate after an acute myocardial infarction could be decreased effectively due to this novel cutting-edge technique. Today’s percutaneous MCS could be implanted in the catheter lab via the leg vessels (Seldingers’ technique) directly to the humans heart within an implantation time of less than 15 minutes. Self-expanding and especially pulsatile catheter-based MCS like the PERKAT heart pumps will offer clinicians a further physiologically optimized therapy option and aim to save additional multiple thousands of lives annually.
Link:
https://www.bm-t.de/2020/neuartige-herzpumpen-fuer-akutpatienten-novapump-sichert-siebenstellige-finanzierungsrunde-mit-internationalem-investorenkonsortium/
https://www.htgf.de/de/htgf-series-a-finanzierung-novapump/?utm_source=pr&utm_medium=pm&utm_content=pm&utm_campaign=NovaPump